Kyverna Therapeutics (KYTX) Cash from Investing Activities (2023 - 2026)

Kyverna Therapeutics (KYTX) has 4 years of Cash from Investing Activities data on file, last reported at -$50.2 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 999.98% year-over-year to -$50.2 million; the trailing twelve-month figure through Mar 2026 stood at -$15.8 million (up 51.41% YoY), and the FY2025 full-year result was $40.0 million, up 124.87% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$50.2 million, down from -$17.3 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $31.7 million in Q4 2023 and bottomed at -$122.9 million in Q1 2024.
• The 4-year median for Cash from Investing Activities is $676000.0 (2024), against an average of -$13.8 million.
• The widest annual swing landed in 2024, when Cash from Investing Activities slumped 2263933.33%; it then surged 3236.83% in 2025.
• A 4-year view of Cash from Investing Activities shows it stood at $31.7 million in 2023, then slipped by 7.76% to $29.2 million in 2024, then tumbled by 159.16% to -$17.3 million in 2025, then plunged by 190.4% to -$50.2 million in 2026.
• The last three Cash from Investing Activities figures came in at -$50.2 million (Q1 2026), -$17.3 million (Q4 2025), and $22.6 million (Q3 2025), per Business Quant data.

Peer Comparison